APRE

Aprea Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
$3131k shares
BuyMar 31, 2026
$0.001
--
Peters RichardDirector
$124123.9k shares
BuyMar 31, 2026
$0.001
--
Peters RichardDirector
$85k123.9k shares
BuyMar 31, 2026
$0.683
--
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
$21k31k shares
BuyMar 31, 2026
$0.683
--
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
$4.4k5.7k shares
BuyJan 30, 2026
$0.765
--
Gilad OrenDirector, Officer: President/CEO
$25k28.1k shares
BuyJan 30, 2026
$0.89
--

News

globenewswire.comAprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumorsglobenewswire.comJun 1zacks.comAprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Knowzacks.comMay 21globenewswire.comAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updateglobenewswire.comMay 13247wallst.comHere Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More247wallst.comMay 7globenewswire.comAprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meetingglobenewswire.comApr 21